172 related articles for article (PubMed ID: 20959004)
1. Characterization of human adenovirus 35 and derivation of complex vectors.
McVey D; Zuber M; Ettyreddy D; Reiter CD; Brough DE; Nabel GJ; King CR; Gall JG
Virol J; 2010 Oct; 7():276. PubMed ID: 20959004
[TBL] [Abstract][Full Text] [Related]
2. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
4. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
5. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
6. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.
Brough DE; Lizonova A; Hsu C; Kulesa VA; Kovesdi I
J Virol; 1996 Sep; 70(9):6497-501. PubMed ID: 8709289
[TBL] [Abstract][Full Text] [Related]
7. Human adenovirus type 35: nucleotide sequence and vector development.
Gao W; Robbins PD; Gambotto A
Gene Ther; 2003 Nov; 10(23):1941-9. PubMed ID: 14528318
[TBL] [Abstract][Full Text] [Related]
8. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.
Gao GP; Yang Y; Wilson JM
J Virol; 1996 Dec; 70(12):8934-43. PubMed ID: 8971023
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
10. Induction of endogenous genes following infection of human endothelial cells with an E1(-) E4(+) adenovirus gene transfer vector.
Ramalingam R; Rafii S; Worgall S; Hackett NR; Crystal RG
J Virol; 1999 Dec; 73(12):10183-90. PubMed ID: 10559334
[TBL] [Abstract][Full Text] [Related]
11. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.
Havenga M; Vogels R; Zuijdgeest D; Radosevic K; Mueller S; Sieuwerts M; Weichold F; Damen I; Kaspers J; Lemckert A; van Meerendonk M; van der Vlugt R; Holterman L; Hone D; Skeiky Y; Mintardjo R; Gillissen G; Barouch D; Sadoff J; Goudsmit J
J Gen Virol; 2006 Aug; 87(Pt 8):2135-2143. PubMed ID: 16847108
[TBL] [Abstract][Full Text] [Related]
12. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches.
Murakami P; Havenga M; Fawaz F; Vogels R; Marzio G; Pungor E; Files J; Do L; Goudsmit J; McCaman M
J Virol; 2004 Jun; 78(12):6200-8. PubMed ID: 15163713
[TBL] [Abstract][Full Text] [Related]
13. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
14. Efficient mobilization of E1-deleted adenovirus type 5 vectors by wild-type adenoviruses of other serotypes.
Rademaker HJ; El Hassan MAA; Versteeg GA; Rabelink MJWE; Hoeben RC
J Gen Virol; 2002 Jun; 83(Pt 6):1311-1314. PubMed ID: 12029145
[TBL] [Abstract][Full Text] [Related]
15. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
16. Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination.
Wu C; Lei X; Wang J; Hung T
J Virol Methods; 2011 Oct; 177(1):55-63. PubMed ID: 21763350
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.
Hehir KM; Armentano D; Cardoza LM; Choquette TL; Berthelette PB; White GA; Couture LA; Everton MB; Keegan J; Martin JM; Pratt DA; Smith MP; Smith AE; Wadsworth SC
J Virol; 1996 Dec; 70(12):8459-67. PubMed ID: 8970968
[TBL] [Abstract][Full Text] [Related]
18. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
19. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
Lieber A; He CY; Kirillova I; Kay MA
J Virol; 1996 Dec; 70(12):8944-60. PubMed ID: 8971024
[TBL] [Abstract][Full Text] [Related]
20. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
